TF1 and TF2B markedly reduced the replication of the ZIKV/Z16006 toxic strain in BHK and Vero cells by obstructing both the replication and release of ZIKVTF2B enhances the survival rate of mice infected with ZIKVThe treatment with TF2B notably diminished the levels of cytokines (such as IL‐6, IL‐1β, and TNF‐α) along with chemokines (including CCL2, CCL5, and CXCL10) that were triggered by ZIKV infection. This evidence concerns the gene CXCL10 and Zika virus infectious disease.